Today, LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced that it has reached an agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to transfer the exclusive development and commercialization rights of NBTXR3, a potential first-in-class radiosensitizer currently in development, in China, South Korea, Singapore, and Thailand to Janssen.
Under the terms of the agreement, LianBio will receive a one-time payment of $25 million. In addition, LianBio is eligible to receive a sales milestone payment of $5 million. Upon completion of the transaction, LianBio will support the transition of the asset to Janssen, with a transition period not exceeding six months.In July 2023, Nanobiotix granted Janssen the license to co-develop and commercialize NBTXR3 globally (excluding the regions previously licensed to LianBio).Konstantin Poukalov, Executive Chairman of LianBio's Board of Directors, stated: "NBTXR3 has demonstrated its potential to improve treatment outcomes for a variety of high-demand solid tumor indications. We believe this transaction will build on the strong foundation LianBio has already established for NBTXR3 in Asia.""Nanobiotix Co-founder and Executive Chairman Laurent Levy stated, 'LianBio has been a crucial partner in the ongoing NANORAY-312 clinical trial for NBTXR3 in treating head and neck squamous cell carcinoma. We look forward to continuing the clinical development of NBTXR3 in Asia, bringing new treatment options to those in need globally.'"Follow the official account below to explore the world with you!
